NEW YORK (GenomeWeb News) – MDxHealth today said that it has signed a partnership with a subsidiary of Sumitomo to bring the firm's molecular diagnostics products to the Japanese market.

Liege, Belgium-based MDxHealth said that Sumitomo subsidiary Summit Pharmaceuticals International will market its pharmaco molecular diagnostic epigenetic technologies and products. Specifically, Summit will aim to provide companion diagnostics to pharmaceutical firms in the Japanese market.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: Icelandic genome sequences, approach to increase CRISPR efficiency, and more.

Testing showing "genetic incompatibilities" have led thousands of couples in Saudi Arabia to call off their weddings, the BBC reports.

Decode Genetics' ability to tell Icelanders, even ones the company hasn't sequenced, about their disease risk brings up ethical questions.

Genetic analysis of Britain's King Richard III and modern descendants of his relatives indicate breaks in the male line.